1. Peura DA, Crowe SE. Helicobacter pylori. In: Feldman M, Friedman LS, Brandt LJ. Sleisenger & Fordtran’s Gastrointestinal and Liver Disease. 9th ed. Philadelphia: Saunders Elsevier, 2010; chap 50.
2. Tonkic A, Tonkic M, Lehours P, Mégraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17 (Suppl. 1): 1–8.
3. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1 (8336): 1273–5.
4. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol 2014; 11 (10): 628–38.
5. Маев И.В., Самсонов А.А., Андреев Д.Н. и др. Клиническое значение инфекции Helicobacter pylori. Клин. медицина. 2013; 8: 4–12.
6. Li HC, Collins RН Jr. Gastrointestinal Lymphomas. In: Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 9th ed. Philadelphia: Saunders Elsevier 2010.
7. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175–6.
8. Parsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267–71.
9. Nakamura S, Yao T, Aoyagi K et al. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients. Cancer 1997; 79: 3–11.
10. Park JB, Koo JS. Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2014; 20 (11): 2751–9.
11. Nakamura S, Matsumoto T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: recent progress in pathogenesis and management. World J Gastroenterol 2013; 19 (45): 8181–7.
12. Nakamura S, Sugiyama T, Matsumoto Т et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507–13.
13. Yoshino T, Miyake K, Ichimura K et al. Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 2000; 24: 688–93.
14. Zaki M, Schubert ML. Helicobacter pylori and gastric lymphoma. Gastroenterology 1995; 108: 610–2.
15. Nakamura S, Matsumoto T. Gastrointestinal lymphoma: recent advances in diagnosis and treatment. Digestion 2013; 87: 182–8.
16. Isaacson PG, Chott A, Nakamura S et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In: Swerdlow SH, Campo E, Harris NL et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC, 2008; 214–7.
17. Amer MH, el-Akkad S. Gastrointestinal lymphoma in adults: clinical features and management of 300 cases. Gastroenterology 1994; 106: 846–58.
18. Genta RM, Hamner HW, Graham DY. Gastric lymphoid follicles in Helicobacter pylori infection: frequency, distribution, and response to triple therapy. Hum Pathol 1993; 24: 577–83.
19. Nagai S, Mimuro H, Yamada T et al. Role of Peyer's patches in the induction of Helicobacter pylori – induced gastritis. Proc Natl Acad Sci USA 2007; 104: 8971–6.
20. Hussell T, Isaacson PG, Crabtree JE, Spencer J. Helicobacter pylori – specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 1996; 178: 122–7.
21. Craig VJ, Cogliatti SB, Arnold I et al. B-cell receptor signaling and CD40 ligand-independent T cell help cooperate in Helicobacter-induced MALT lymphomagenesis. Leukemia 2010; 24: 1186–96.
22. Lin WC, Tsai HF, Kuo SH et al. Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res 2010; 70 (14): 5740–8.
23. Munari F, Lonardi S, Cassatella MA et al. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood 2011; 117: 6612–6.
24. Planelles L, Medema JP, Hahne M, Hardenberg G. The expanding role of APRIL in cancer and immunity. Curr Mol Med 2008; 8: 829–44.
25. Witkowska M, Smolewski P. Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm 2013; 2013: 523170.
26. Bertoni F, Gascoyne RD. Pathobiology and molecular basis of MALT lymphoma. In: Cavalli F, Stein H, Zucca E. Extranodal Lymphomas Pathology and Management. Informa Health Care London, 2008.
27. Du MQ. MALT lymphoma: many roads lead to nuclear factor-κb activation. Histopathology 2011; 58: 26–38.
28. Farinha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 6370–8.
29. Hamoudi RA, Appert A, Ye H et al. Differential expression of NF-kB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanism. Leukemia 2010; 24 (8): 1487–97.
30. Ye H, Liu H, Attygalle A et al. Variable frequencies of t(11; 18)(q21; q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003; 102 (3): 1012–8.
31. Liu H, Ye H, Ruskone-Fourmestraux A et al. T(11; 18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286–94.
32. Isaacson PG, Du MQ. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4: 644–53.
33. Streubel B, Lamprecht A, Dierlamm J et al. T(14; 18)(q32; q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 2335–9.
34. Jiang W, Li L, Tang Y et al. Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. Med Oncol 2012; 29 (5): 3352–9.
35. Zullo A, Hassan C, Andriani A et al. Primary low-grade and high-grade gastric MALT-lymphoma presentation: a systematic review. J Clin Gastroenterol 2010; 44: 340–4.
36. Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol 2008; 19: 1992–9.
37. Taal BG, Boot H, van Heerde P et al. Primary non-Hodgkin lymphoma of the stomach: Endoscopic pattern and prognosis in low versus high grade malignancy in relation to the MALT concept. Gut 1996; 39: 556–61.
38. Wotherspoon AC, Doglioni C, Isaacson PG. Low-grade gastric B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): A multifocal disease. Histopathology 1992; 20: 29–34.
39. Fischbach W, Dragosics B, Kolve-Goebeler ME et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German–Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology 2000; 119: 1191–202.
40. Montalbán C, Castrillo JM, Abraira V et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol 1995; 6: 355–62.
41. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747–58.
42. Rohatiner A, d’Amore F, Coiffier B et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397–400.
43. Zullo A, Hassan C, Cristofari F et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105–10.
44. Malfertheiner P, Megraud F, O’Morain C et al. European Helicobacter Study Group. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut 2012; 61 (7): 646–64.
45. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Эрадикационная терапия инфекции Helicobacter pylori: обзор мировых тенденций. Терапевт. арх. 2014; 3: 94–9.
46. Zullo A, Hassan C, Ridola L et al. Gastric MALT lymphoma: old and new insights. Ann Gastroenterol 2014; 27 (1): 27–33.
47. Park SK, Jung HY, Kim DH et al. Regression of advanced gastric MALT Lymphoma after the eradication of Helicobacter pylori. Gut Liver 2012; 6: 270–4.
48. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Антибиотикорезистентность Helicobacter pylori: от клинического значения до молекулярных механизмов. Лечащий врач. 2014; 2: 34–40.
49. Кучерявый Ю.А., Андреев Д.Н., Баркалова Е.В. Клинико-молекулярные аспекты резистентности Helicobacter pylori к антибактериальным препаратам. Мед. совет. 2013; 10: 11–5.
50. Маев И.В., Кучерявый Ю.А., Андреев Д.Н. Причины неэффективности антигеликобактерной терапии. РЖГГК. 2013; 6: 62–72.
51. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J 2014; 30: 134–40.
52. Park HS, Kim YJ, Yang WI et al. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 2010; 16: 2158–62.
53. Zullo A, Hassan C, Ridola L et al. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol 2013; 47 (10): 824–7.
54. Yoon SS, Coit DG, Portlock CS, Karpeh MS. The diminishing role of surgery in the treatment of gastric lymphoma. Ann Surg 2004; 240: 28–37.
55. Kuo SH, Chen LT, Wu MS et al. Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: Need for a revisit of surgical treatment. Ann Surg 2008; 247: 265–9.
56. Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157–64.
57. Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: A review of treatment options. Int J Radiat Oncol Biol Phys 2000; 46: 1093–103.
58. Yahalom J. MALT lymphomas: A radiation oncology viewpoint. Ann Hematol 2001; 80 (Suppl. 3): B100–5.
59. Hammel P, Haioun C, Chaumette MT et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995; 13: 2524–9.
60. Nakamura S, Matsumoto T, Suekane H et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005; 104: 532–40.
61. Martinelli G, Laszlo D, Ferreri AJ et al. Clinical activity of rituximab in gastric marginal zone non- Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979–83.
62. Zucca E, Conconi A, Laszlo D et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013; 31: 565–72.
63. Nakamura M, Takahashi T, Matsui H et al. New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib. Curr Pharm Des 2014; 20 (7): 1097–103.

И.В.Маев, Д.Н.Андреев, Ю.А.Кучерявый

ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава России